182 related articles for article (PubMed ID: 31189618)
21. Real-World Clinical and Patient-Reported Outcomes from the Longitudinal Telotristat Ethyl Treatment Registry of Patients with Neuroendocrine Tumors.
Li D; Darden C; Osman N; Sayeed S; Jackson L; Garbinsky D; Chauhan A
Cancer Manag Res; 2022; 14():3009-3020. PubMed ID: 36262750
[TBL] [Abstract][Full Text] [Related]
22. Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach.
Gelhorn HL; Kulke MH; O'Dorisio T; Yang QM; Jackson J; Jackson S; Boehm KA; Law L; Kostelec J; Auguste P; Lapuerta P
Clin Ther; 2016 Apr; 38(4):759-68. PubMed ID: 27041406
[TBL] [Abstract][Full Text] [Related]
23. Telotristat Ethyl: First Global Approval.
Markham A
Drugs; 2017 May; 77(7):793-798. PubMed ID: 28382568
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.
Hörsch D; Anthony L; Gross DJ; Valle JW; Welin S; Benavent M; Caplin M; Pavel M; Bergsland E; Öberg K; Kassler-Taub KB; Binder P; Banks P; Lapuerta P; Kulke MH
Neuroendocrinology; 2022; 112(3):298-310. PubMed ID: 33940581
[TBL] [Abstract][Full Text] [Related]
25. Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review.
Wolin EM; Benson Iii AB
Oncology; 2019; 96(6):273-289. PubMed ID: 31018209
[TBL] [Abstract][Full Text] [Related]
26. Regarding "TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World".
Hota S; Srirajaskanthan R
Oncologist; 2020 Jul; 25(7):e1132. PubMed ID: 32420675
[TBL] [Abstract][Full Text] [Related]
27. Weight Maintenance up to 48 Weeks in Patients With Carcinoid Syndrome Treated With Telotristat Ethyl: Pooled Data From the Open-Label Extensions of the Phase III Clinical Trials TELESTAR and TELECAST.
Srirajaskanthan R; Pavel M; Kulke M; Clement D; Houchard A; Keeber L; Weickert MO
Clin Ther; 2021 Oct; 43(10):1779-1785. PubMed ID: 34598813
[TBL] [Abstract][Full Text] [Related]
28. Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome.
Koumarianou A; Daskalakis K; Tsoli M; Kaltsas G; Pavel M
J Neuroendocrinol; 2022 Jul; 34(7):e13174. PubMed ID: 35794780
[TBL] [Abstract][Full Text] [Related]
29. Telotristat ethyl (Xermelo) for carcinoid syndrome diarrhea.
Med Lett Drugs Ther; 2017 Jul; 59(1525):119-120. PubMed ID: 28699933
[No Abstract] [Full Text] [Related]
30. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Martínez-Sáez O; Grande E
Oncologist; 2016 Jun; 21(6):701-7. PubMed ID: 27107003
[TBL] [Abstract][Full Text] [Related]
31. Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study.
Morse MA; Liu E; Joish VN; Huynh L; Cheng M; Duh MS; Seth K; Lapuerta P; Metz DC
Cancer Manag Res; 2020; 12():6607-6614. PubMed ID: 32801896
[TBL] [Abstract][Full Text] [Related]
32. Effect of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells.
Herrera-Martínez AD; Feelders RA; Van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Castaño JP; de Herder WW; Hofland LJ
Neuroendocrinology; 2020; 110(5):351-363. PubMed ID: 31319410
[TBL] [Abstract][Full Text] [Related]
33. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
[TBL] [Abstract][Full Text] [Related]
34. Developments in the treatment of carcinoid syndrome - impact of telotristat.
Chan DL; Singh S
Ther Clin Risk Manag; 2018; 14():323-329. PubMed ID: 29503551
[TBL] [Abstract][Full Text] [Related]
35. Does Telotristat Have a Role in Preventing Carcinoid Heart Disease?
Herrera-Martínez AD; Fuentes-Fayos AC; Sanchez-Sanchez R; Montero AJ; Sarmento-Cabral A; Gálvez-Moreno MA; Gahete MD; Luque RM
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396713
[TBL] [Abstract][Full Text] [Related]
36. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
Fisher GA; Wolin EM; Liyanage N; Pitman Lowenthal S; Mirakhur B; Pommier RF; Shaheen M; Vinik A;
Oncologist; 2018 Jan; 23(1):16-24. PubMed ID: 29038234
[TBL] [Abstract][Full Text] [Related]
37. Management of carcinoid syndrome: a systematic review and meta-analysis.
Hofland J; Herrera-Martínez AD; Zandee WT; de Herder WW
Endocr Relat Cancer; 2019 Mar; 26(3):R145-R156. PubMed ID: 30608900
[TBL] [Abstract][Full Text] [Related]
38. Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues.
Joish VN; Perez-Olle R; Lapuerta P; Dharba S; Zacks J
Clin Ther; 2019 Sep; 41(9):1716-1723.e2. PubMed ID: 31326125
[TBL] [Abstract][Full Text] [Related]
39. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
[TBL] [Abstract][Full Text] [Related]
40. Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension.
Kasi PM
Pancreas; 2018 Jan; 47(1):e2. PubMed ID: 29232344
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
